Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.Leukemia Research.  74:64-67. 2018
2018 Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.Leukemia2018
2018 Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.Leukemia2018
2018 A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.Blood.  132:1125-1133. 2018
2018 Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.Blood.  131:2782-2788. 2018
2018 Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.New England Journal of Medicine.  378:2386-2398. 2018
2018 Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.Leukemia & Lymphoma.  1-4. 2018
2018 Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.Leukemia2018
2018 Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).Leukemia Research.  67:17-20. 2018
2018 Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.Blood.  131:1415-1424. 2018
2018 Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.Biopreservation and Biobanking.  16:42-52. 2018
2018 A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.Blood.  131:387-396. 2018
2017 Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.American Journal of Hematology.  93:E49-E52. 2017
2017 Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.Journal of Clinical Oncology.  35:2745-2753. 2017
2017 Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.Cancer.  123:2472-2481. 2017
2017 Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraBlood.  129:1763-1767. 2017
2017 Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.Blood Cancer Journal.  7:e520. 2017
2017 Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208.Journal of Cancer Survivorship.  11:32-40. 2017
2017 Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.Transfusion.  57:289-295. 2017
2017 Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Lancet Oncology.  18:1061-1075. 2017
2016 Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.Leukemia.  30:2080-2083. 2016
2016 Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.BMC Cancer.  16:652. 2016
2016 Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.Leukemia.  30:1779-1780. 2016
2016 Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.Leukemia Research.  42:68-74. 2016
2016 Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.British Journal of Haematology.  172:384-391. 2016
2016 In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.PLoS ONE.  11:e0166891. 2016
2016 Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.Haematologica.  101:e284-e286. 2016
2015 Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.Haematologica.  100:e409-e411. 2015
2015 Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.Lancet Oncology.  16:1025-1036. 2015
2015 In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.Mayo Clinic Proceedings.  90:996-1000. 2015
2015 Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.Clinical Lymphoma, Myeloma and Leukemia.  15:443-449. 2015
2015 Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.British Journal of Haematology.  169:534-543. 2015
2015 Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.Journal of Clinical Oncology.  33:1252-1257. 2015
2015 Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.Haematologica.  100:331-335. 2015
2015 Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.Biology of Blood and Marrow Transplantation.  21:559-564. 2015
2015 Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.American Journal of Hematology.  90:242-249. 2015
2015 Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014.Current opinion in hematology.  22:108-115. 2015
2015 Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.Blood.  125:1367-1376. 2015
2015 Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.Leukemia Research.  39:183-191. 2015
2014 Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.British Journal of Haematology.  167:62-68. 2014
2014 Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.British Journal of Haematology.  166:352-359. 2014
2014 Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.Journal of Clinical Oncology.  32:1242-1248. 2014
2014 Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.Leukemia Research.  38:329-333. 2014
2014 Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.Leukemia.  28:289-292. 2014
2014 Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Clinical Cancer Research.  20:490-498. 2014
2014 A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.PLoS ONE.  9:e108694. 2014
2013 Expert insights into the contemporary management of older adults with acute myeloid leukemiaCancer Control : Journal of the Moffitt Cancer Center.  20:5-16. 2013
2013 A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.Blood.  122:3432-3439. 2013
2013 Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).Investigational New Drugs.  31:1023-1034. 2013
2013 A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.Blood.  121:4854-4860. 2013
2012 Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.Expert Review of Anticancer Therapy.  12:1289-1297. 2012
2012 Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.Leukemia & Lymphoma.  53:435-440. 2012
2011 Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia.Blood.  118:5914-5917. 2011
2011 Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.Blood.  118:4258-4264. 2011
2011 Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.Clinical Advances in Hematology and Oncology.  9:734-745. 2011
2011 A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.Clinical Cancer Research.  17:2679-2692. 2011
2011 Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.Blood.  117:3294-3301. 2011
2011 A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.Cancer.  117:1253-1261. 2011
2011 Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer.Expert Opinion on Therapeutic Targets.  15:253-264. 2011
2010 Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.Blood.  116:4958-4967. 2010
2010 Has there been progress in the treatment of older patients with acute myeloid leukemia?Baillieres Clinical Haematology.  23:495-501. 2010
2010 NF1 inactivation in adult acute myelogenous leukemia.Clinical Cancer Research.  16:4135-4147. 2010
2010 Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.Blood.  116:71-80. 2010
2010 Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.Journal of Clinical Oncology.  28:549-555. 2010
2010 Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.British Journal of Haematology.  148:48-58. 2010
2009 NCCN task force report: molecular markers in leukemias and lymphomas.Journal of the National Comprehensive Cancer Network.  7 Suppl 4:S1-34. 2009
2009 Chronic myelogenous leukemiaJournal of the National Comprehensive Cancer Network.  7:984-1023. 2009
2009 Myeloid growth factors.Journal of the National Comprehensive Cancer Network.  7:64-83. 2009
2008 Acute myeloid leukemia.Journal of the National Comprehensive Cancer Network.  6:962-993. 2008
2008 Myelodysplastic syndromes.Journal of the National Comprehensive Cancer Network.  6:902-926. 2008
2008 Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.Blood.  112:1993-2003. 2008
2008 Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.Cancer Research.  68:1012-1021. 2008
2008 Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Blood.  111:1584-1593. 2008
2007 In vitro and in silico analysis of annexin V binding to lymphocytes as a biomarker in emergency department sepsis studies.Academic Emergency Medicine.  14:763-771. 2007
2007 Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.  27:970-979. 2007
2007 Chronic myelogenous leukemia.Journal of the National Comprehensive Cancer Network.  5:474-496. 2007
2007 Myeloid growth factors. Clinical practice guidelines in oncology.Journal of the National Comprehensive Cancer Network.  5:188-202. 2007
2007 Prognostic factors in elderly patients with AML and the implications for treatment.Hematology online (ASH).  420-428. 2007
2006 Acute myeloid leukemia clinical practice guidelines in oncology.Journal of the National Comprehensive Cancer Network.  4:16-36. 2006
2006 Myelodysplastic syndromes clinical practice guidelines in oncology.Journal of the National Comprehensive Cancer Network.  4:58-77. 2006
2005 Chronic myelogenous leukemia: Clinical practice guidelines in oncologyJournal of the National Comprehensive Cancer Network.  3:732-755. 2005
2004 Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.Current Hematology Reports.  3:47-53. 2004
2003 Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.Journal of Clinical Oncology.  21:3512-3519. 2003
2003 Recent progress in the treatment of myelodysplastic syndrome in adult patients.Current Opinion in Oncology.  15:1-9. 2003
2002 Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).Leukemia.  16:1627-1636. 2002
2000 NCCN Practice Guidelines for Acute Myelogenous Leukemia.Oncology.  14:53-61. 2000
2000 NCCN Practice Guidelines for Chronic Myelogenous Leukemia.Oncology.  14:229-240. 2000
2000 Reversible pulmonary hypertension in POEMS syndrome--another etiology of triggered pulmonary vasculopathy?Canadian Journal of Cardiology.  16:1007-1012. 2000
1988 Nucleotide sequence and expression of the human skeletal alpha-actin gene: evolution of functional regulatory domains.Genomics.  3:323-336. 1988
1988 Modulation of microfilament protein composition by transfected cytoskeletal actin genes.Molecular and Cellular Biology.  8:1790-1794. 1988
1988 Structure, chromosome location, and expression of the human gamma-actin gene: differential evolution, location, and expression of the cytoskeletal beta- and gamma-actin genes.Molecular and Cellular Biology.  8:1775-1789. 1988
1988 Cytoskeletal actin gene families of Xenopus borealis and Xenopus laevis.Journal of Molecular Evolution.  27:17-28. 1988
1986 Nucleotide sequence of the human gamma cytoskeletal actin mRNA: anomalous evolution of vertebrate non-muscle actin genes.Nucleic Acids Research.  14:5275-5294. 1986
1981 Histone gene clusters of the newt notophthalmus are separated by long tracts of satellite DNA.Cell.  24:639-647. 1981
1981 Characterization of a cloned histone gene cluster of the newt Notophthalamus viridescens.Nucleic Acids Research.  9:2281-2295. 1981
1981 Histone genes are located at the sphere loci of newt lampbrush chromosomes.Chromosoma.  84:159-171. 1981
1980 Satellite DNA is transcribed on lampbrush chromosomes.Nature.  283:686-688. 1980
1980 Cytological evidence of transcription of highly repeated DNA sequences during the lampbrush stage in Triturus cristatus carnifex.Chromosoma.  80:289-307. 1980

Chapter

Year Title Altmetric
2014 Cytogenetics and Prognostic Models in Myelodysplastic Syndromes.  106-112. 2014

Principal Investigator On

  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2018 - 2023
  • UAB 1640-Phase II Trial of Vosaroxin in Combination with Infusional Cytarabine in Patients with Untreated AML  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2016 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2016 - 2021
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2015 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by AMGEN, INC. 2014 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • SWOG Network Group Operations Center of the NCTN  awarded by OREGON HEALTH SCIENCES UNIVERSITY 2014 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2018
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2016 - 2018
  • Southwest Oncology Group Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP 2013 - 2018
  • Private Grant  awarded by IMMUNOGEN, INC. 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2016 - 2018
  • Southwest Oncology Group Clinical Trials Initiative Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP 2013 - 2018
  • Private Grant  awarded by CELATOR PHARMACEUTICALS, INC. 2012 - 2017
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2017
  • Private Grant  awarded by Janssen 2016 - 2017
  • Private Grant  awarded by AGIOS 2015 - 2017
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2017
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by IMMUNOGEN, INC. 2016 - 2017
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015 - 2017
  • Comprehensive Cancer Center Core Support Grant - Protocol Review and Monitoring System  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2014 - 2016
  • Active - NCI Clinical Trial Reporting Program - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2013 - 2014
  • SWOG Treatment Grant (U10 CA032102)  awarded by Oregon Health & Science University 2013 - 2014
  • Southwest Oncology Group Operations Office Grant  awarded by University of Michigan 2012 - 2013
  • Investigator On

  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by ABBVIE INC 2018 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Comprehensive Cancer Center Core Support Grant - Adiministrative Core  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • Private Grant  awarded by Gilead Sciences 2013 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2013 - 2019
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2019
  • Private Grant  awarded by Genentech 2013 - 2018
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Private Grant  awarded by GlaxoSmithKline 2013 - 2016
  • Private Grant  awarded by MedImmune 2014 - 2016
  • Private Grant  awarded by ELI LILLY AND COMPANY 2013 - 2016
  • Active - Senior Leadership - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015 - 2016
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2014 - 2016
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2013 - 2015
  • Private Grant  awarded by CYCLACEL LTD 2014 - 2015
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2013 - 2015
  • Private Grant  awarded by ABBVIE INC 2013 - 2014
  • Private Grant  awarded by SPECTRUM PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2014
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2013
  • Full Name

  • Harry Erba
  • Blazerid

  • hperba